VIRBAGEN OMEGA 10 INTERFERON FOR DOGS AND CATS Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbagen omega 10 interferon for dogs and cats

virbac (australia) pty ltd - recombinant omega interferon of feline origin - parenteral liquid/solution/suspension - recombinant omega interferon of feline origin vaccine active 10.0 mu/ml - immunotherapy - cat | dog - adult | cat - queen | cat - tom | kitten - canine parvovirus | feline calicivirus | calicivirus (feline) | fcv | parvovirus

Omegaven [see label] Emulsion for IV Infusion Филиппины - английский - FDA (Food And Drug Administration)

omegaven [see label] emulsion for iv infusion

(for) fresenius kabi deutschland gmbh; importer: fresenius - kabi philippines inc.; distributor: fresenius - kabi philippines inc. - highly refined fish oil - emulsion for iv infusion - [see label]

Cefuroxime Dr. Eberth 750 mg Powder for solution for injection/infusion Мальта - английский - Medicines Authority

cefuroxime dr. eberth 750 mg powder for solution for injection/infusion

dr. friedrich eberth arzneimittel gmbh am bahnhof 2, ursensollen 92289, germany - cefuroxime sodium - powder for solution for infusion or injection - cefuroxime sodium 750 mg - antibacterials for systemic use

Cefuroxime Dr. Eberth 1500 mg Powder for solution for injection/infusion Мальта - английский - Medicines Authority

cefuroxime dr. eberth 1500 mg powder for solution for injection/infusion

dr. friedrich eberth arzneimittel gmbh am bahnhof 2, ursensollen 92289, germany - cefuroxime sodium - powder for solution for infusion or injection - cefuroxime sodium 1500 mg - antibacterials for systemic use

MITOMYCIN OMEGAPHARM mitomycin powder for injection 20mg vial Австралия - английский - Department of Health (Therapeutic Goods Administration)

mitomycin omegapharm mitomycin powder for injection 20mg vial

omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

MITOMYCIN OMEGAPHARM mitomycin powder for injection 10mg vial Австралия - английский - Department of Health (Therapeutic Goods Administration)

mitomycin omegapharm mitomycin powder for injection 10mg vial

omegapharm - mitomycin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

MITOMYCIN OMEGAPHARM mitomycin powder for injection 2mg vial Австралия - английский - Department of Health (Therapeutic Goods Administration)

mitomycin omegapharm mitomycin powder for injection 2mg vial

omegapharm - mitomycin, quantity: 2 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.

OMEGAVEN- fish oil injection, emulsion Соединенные Штаты - английский - NLM (National Library of Medicine)

omegaven- fish oil injection, emulsion

fresenius kabi usa, llc - fish oil (unii: xgf7l72m0f) (fish oil - unii:xgf7l72m0f) - omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (pnac). limitations of use: - omegaven is not indicated for the prevention of pnac. it has not been demonstrated that omegaven prevents pnac in parenteral nutrition (pn)-dependent patients [see clinical studies (14)]. - it has not been demonstrated that the clinical outcomes observed in patients treated with omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product [see clinical studies (14)]. use of omegaven is contraindicated in patients with: - known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients [see warnings and precautions (5.2)]. - severe hemorrhagic disorders due to a potential effect on platelet aggregation. - severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations greater than 1,000 mg/dl) [see warnings and precautions (5.6)]. risk summary there are no av